Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. (ver web)
(coautores junto a González JL, Prior C, Castellano D, Mellado B, Gallardo E, Perez JL,, Villanueva X, Albanell J, Calvo A). Ann Oncol. 2011 Mar 21.SEOM clinical guidelines for the treatment of invasive bladder cancer. (ver web)
Mammographic features of screening detected pT1 (a-b) invasive breast usin BI-RADS lexicon.
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. (ver web)
(coautores junto a González-Larriba JL, Prior C, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A). Epub 2011 Mar 21.